---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-096784"
form_type: "8-K"
ticker: "ELAB"
cik: "0001840563"
company_name: "PMGC Holdings Inc."
filed_at: "2026-09-02T21:04:24+00:00"
generated_at: "2026-09-02T21:06:09.026638+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMGC's NorthStrive expands AI drug program with Yuva, advances four compounds

## Summary
- NorthStrive (PMGC) and Yuva execute First Amendment launching three-phase Expansion Program for four AI-discovered compounds.
- Program builds on July 1, 2026 Phase III results (significant ANT1 increases); ~6 months to lead compound nomination.
- Amendment grants right of first refusal for exclusive cardiometabolic license beyond Cardiac Diseases and Obesity.
- Company increased authorized shares to 1.5B (1B common, 500M preferred) via Certificate of Amendment, 60.34% approval.

## SEC filing metadata
- accession: 0001213900-26-096784
- form_type: 8-K
- ticker: ELAB
- cik: 0001840563
- company_name: PMGC Holdings Inc.
- filed_at: 2026-09-02T21:04:24+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/0001213900-26-096784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840563/000121390026096784/ea0304419-8k_pmgchold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-096784
- JSON: https://secwatch.observer/filing/0001213900-26-096784.json
- Plain text: https://secwatch.observer/filing/0001213900-26-096784.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.